Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET

Company Participants

Alfred Sandrock - Chief Executive Officer

Peter Pfreundschuh - Chief Financial Officer

Todd Carter - Chief Scientific Officer

Conference Call Participants

Jack Allen - Robert W. Baird

Philip Nadeau - Cowen and Company

Laura Chico - Wedbush

Yung Zhong - BTIG

Dane Leone - Raymond James

Sumant Kulkarni - Canaccord Genuity

Operator

Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that the call is being recorded at the company’s request. A replay of today’s call will be available on the investor section of the company’s website approximately two hours after the conclusion of the call.

I would now like to turn the call over to Peter Pfreundschuh, Chief Financial Officer.

Peter Pfreundschuh

Thank you and good morning. We issued our third quarter financial results press release this morning. The press release and 10-Q are available on our website. We plan to be very efficient in today’s call. Accordingly, we are going to provide a brief summary of key highlights from the quarter and reserve the majority of time for your Q&A.

In a moment, I will turn over the call to Al. Before I do this, I want to remind everyone that during this call, Voyager representatives may make forward-looking statement regarding future expectations, plans and prospects. All forward-looking statements are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand a number of the material risks and uncertainties facing the company as described in the company’s annual report on Form 10-K filed with the SEC, as updated by subsequent SEC filings including the company’s most recent quarterly report on Form 10-Q filed this morning. All SEC filings are available on the company’s website.

Now it is my pleasure to turn over the call to Voyager’s Chief Executive Officer, Dr. Al Sandrock.

Alfred Sandrock

Thank you and Pete, and good morning, everyone. I would like to start by summarizing Voyager’s investment thesis. Voyager is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology.

The potential of both disciplines has been constrained by delivery challenges. Gene therapy has been limited by narrow therapeutic windows and associated safety issues. Neurology is limited by the difficulty for getting larger molecules across the blood-brain-barrier.